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Abstract: Influenza is a well known infection of the respiratory system. The main clinical 
manifestations of influenza include fever, sore throat, headache, cough, coryza, and malaise. 
Apart from the well known classical influenza, there are also groups of influenza virus infections 
that are called “atypical infection”. These infections are usually due to a novel influenza virus 
infection. In early 2009, an emerging novel influenza originating from Mexico called swine 
flu was reported. The World Health Organization noted a level VI precaution, the highest level 
precaution possible, for this newest influenza virus infection. As of June 2009, it is not known 
if this disease will be successfully controlled. Finding new drugs and vaccine for the emerging 
swine flu is still required to cope with this emerging worldwide problem.
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Influenza infection
etiology
Influenza is a well known infection.1,2 It is classified as a respiratory system infection. 
The main pathogenic cause of influenza is virus. The influenza virus is a widely 
studied virus in medicine.1,2 As a respiratory tract infection, the influenza virus is 
mainly transmitted via air as an airborne infectious disease.1,2 The pathogenic influenza 
virus can enter into the human body due to the inhalation of infectious air particles.3,4 
The contaminated airborne particles can be generated by sneezing and coughing by 
infected patients.3,4 Specific body secretions that are highly contaminated with influenza 
virus include running nose fluids and saliva. It should also be noted that contaminated 
secretions can be found in spillage and in any used objects for up to two hours.3,4 
If someone contacts the contaminated object, there is a possibility of infection and 
transmission of pathogen can be expected. Recently, Grayson and colleagues said 
that soap and water hand-washing or alcohol-based hand rub was highly effective in 
reducing influenza virus on human hands.15 Hand washing is an important practice to 
control the spread of influenza.5–8
Clinical manifestations
In general, influenza virus can be classified into three main groups, group A, group B, 
and group C.9,10 All groups can cause disease in human beings. Only group A can also 
cause infection in animals. Generally, patients usually develop signs and symptoms 
within two days (range 1–4 days) after contact with the pathogen.11,12 However, the 
isolation of influenza virus may not be seen, hence, transmission of disease can be Biologics: Targets & Therapy 2009:3 378
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possible before signs and symptoms are manifested.11,12 The 
peak of fever can be usually seen in day 3.11,12 The main 
clinical manifestations of influenza include fever, sore throat, 
headache, cough, coryza, and malaise. Due to the nature 
of the virus, the course of illness usually completes within 
one week or on day 9 after the first contact with the pathogen. 
Influenza complications usually start after this period.13 In 
general, the disease burden due to influenza is usually low.14,15 
Hospitalization is usually required for two specific age groups: 
the infant group aged less than six months and the elderly 
group aged more than 65 years. Factors relating to the sever-
ity of influenza include age and underlying personal illness. 
The high-risk population for severe clinical manifestation 
includes the elder group aged more than 65 years,16 the infant 
group aged less than two years,17 patients with human immu-
nodeficiency virus (HIV) infection,18 patients with chronic 
obstructive pulmonary disease and asthma,19 patients with 
congenital heart disease,20 patients on immunosuppressive 
drugs, and patients with prolonged usage of aspirin.
In the general low-risk adult population, the signs and 
symptoms of influenza can be self-limited. There is no need 
for medication. Serious complications21,22 can be seen, such as 
otitis media, pneumonitis,23 myocarditis,24 encephalopathy,25,26 
and Reye’s syndrome.27 As previously noted, the prevalence 
of complication is high in the at-risk groups.21,22 For example, 
up to 10% of infantile cases can develop complications and 
can end up with influenza encephalopathy. The rate of fatality 
in influenza encephalopathy is as high as one third of affected 
cases.25,26
Diagnosis, treatment, and prevention
Clinical diagnosis is generally used for presumptive diagnosis. 
However, the main problem is due to the similarity between 
influenza and other respiratory tract infections. Laboratory 
investigation is required to confirm diagnosis. The basic 
immunological diagnosis is useful.28–38 However, a molecular-
based diagnostic tool is usually required in atypical cases.39–45 
This is because although the immunology-based technique 
is cheaper and faster in diagnosis, it lacks specificity. 
New molecular-based diagnostic tools can provide the most 
specific result since the diagnosis is based on the exact 
sequence of the viral particle. However, molecular-based 
diagnosis is expensive and time-consuming to perform. 
Therefore it might be unavailable and unaffordable for poor 
settings in developing countries.
Since the influenza viral infection can be self-limiting 
in otherwise healthy adults, there is no need for specific 
medication or treatment.46 However, in at-risk cases, 
an antiviral drug treatment is recommended.46–50 The widely 
used antiviral drugs for influenza are amantadine,51 
rimantadine,52 oseltamivir,53 and zanamivir.54–56 Oseltamivir 
and zanamivir are newer drugs with a lower drug-resistant 
rate. These two drugs are also indicated for atypical cases.
At present, a specific influenza vaccine is available for 
prevention and is recommended for the at-risk population, 
especially the elderly.57,58 Jefferson and colleagues noted in 
a Cochrane review that influenza vaccines were effective in 
reducing cases of influenza, but were less effective in reduc-
ing cases of influenza-like illness.59 Jefferson and colleagues 
also noted that influenza vaccines had a modest impact on 
lost working days but there was no sufficient evidence on 
complications.59 In the scenario of an influenza pandemic, 
vaccination is the main hope for disease control.60
Novel influenza virus infection: 
What is it?
Apart from the already mentioned classical influenza virus 
infection, there are also a group of influenza virus infections 
that are called “atypical infection”. These infections are usu-
ally due to a novel influenza virus infection.61,62 Those new 
pathogenic viruses, which usually result from genetic muta-
tions, correspond to atypical infection. The new infection is 
usually recognized as a new emerging infectious disease.63
Zoonosis is usually mentioned for any novel influenza 
virus infection. “Why is zoonosis usually mentioned?” is an 
interesting question. As previously noted, influenza group A 
can infect both human beings and animals. When animals 
live near human beings, the exchange of viruses that each 
side carries can be expected and the final result can be a new, 
emerging zoonosis. This viral transmission scenario is a big 
problem for medicine since new emerging infections are new 
diseases that human beings have never experienced before.
The lack of immunity can be seen since present data indi-
cate that only some older individuals have immunity against 
the current novel influenza A (H1N1).64 At present, most 
physicians are already aware of this ongoing pandemic.
Examples of emerging influenza are well known. The 
case of avian flu65–71 which emerged in the few recent years 
is the best example (Table 1). Avian flu is a novel influenza 
virus infection (owing to H5N1 influenza virus infection). 
This bird-borne disease is still a problem worldwide.65–72 
No specific treatment has been developed yet. Luckily, only 
sporadic cases occurred around the world without pandemic. 
However, another emerging novel influenza originated from 
Mexico in early 2009.73–85 This new infection is called swine 
flu (Table 1). Swine flu is caused by the novel influenza virus, Biologics: Targets & Therapy 2009:3 379
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H1N1 influenza virus. The novel H1N1 influenza virus that 
causes swine flu is the result from genetic reassortment of 
gene segments from not only human H1N1 virus, but North 
American swine flu, Asian swine flu, and avian flu.87 This 
new recombinant virus causes the current pandemic and leads 
to generalized infection worldwide.85 In early June 2009, the 
swine flu, which is now called influenza 2009 is pandemic 
in many countries worldwide (more than 70 countries and 
more than 25,000 infected cases).85 The World Health 
Organization (WHO) noted a level VI precaution, the high-
est level precaution possible, for this newest influenza virus 
infection (Table 2). As of June 2009, it is not known if this 
Table 1 Details of important novel influenza
Aspects Avian flu65–72 Swine flu73–85
  1.  Pathogenic virus  
  2.  related animal  
  3.  Disease burden  
  4.  Pandemic  
  5.  Human to human transmission   
  6. vertical transmission  
  7.  Clinical manifestation  
 
  8. viral receptor in human beings  
  9. vaccine  
10. Treatment by antiviral drug
H5N1 influenza virus. 
Avian. 
High fatality. 
No. 
No evidence. 
No evidence.  
Similar to classical influenza  
with some interesting atypical manifestations 
(such as diarrhea). 
Can be seen in lower respiratory tract. 
Not available. 
Needed, usually with oseltamivir,  
but there are few good outcomes.
Atypical H1N1 influenza virus. 
Swine. 
No high fatality. 
Yes (in 2009). 
Strong evidence. 
No evidence. 
Similar to classical influenza with some interesting 
atypical manifestations (such as nonfebrile illness). 
Can be seen in upper respiratory tract. 
Has been manufactured and approved by the US FDA.86
Suggested, usually with oseltamivir, good outcomes.
Abbreviation: FDA, US Food and Drug Administration.
Table 2 Summary of some problematic points of swine flu infection73–85
Points   Descriptions
1.  Mode of transmission  Human-to-human transmission is confirmed.   This raises serious concerns and leads to a high level of precaution set 
by WHO. 
2.  Natural history  A similar natural history to classical influenza can be seen. However, there is a notification on nonfebrile cases,  
which can be a big problem for detection and surveillance processes. 
3.  epidemiology  Presently swine flu is worldwide.   Thousands of infected cases can be seen. Of interest, in the early stage  
(April–May 2009) the disease was confined in Mexico and nearby countries. Some sporadic cases were observed 
from distant countries. The main infected group was adults with a history of traveling to/from the infected areas.  
This reflects the importance of traveler medicine. However, after the first period, human-to-human transmission 
becomes an important emerging issue. New infectious cases in distant countries with no history of traveling to the 
problematic infected areas could be detected (such as in Japan and Thailand). 
4.  Diagnosis  Diagnosis by clinical manifestation shows difficulties in separating swine flu from classical influenza and other 
common respiratory tract infections. This is a serious problem for clinical diagnosis. The basic immunological 
diagnostic tool can confirm only H1N1 infection, but not typical or atypical. Molecular-based detection is required.  
A real-time PCr for diagnosis is available. However, the problems of over-register or under-diagnosis in setting due to 
lack of a gold standard can be expected. 
5. Treatment  Pharmacological treatment with oseltamivir is the present treatment, although it can not yet be confirmed if it is the 
best measure.   With the present sign of emerging pandemic, there are several problems with the use of oseltamivir. 
These problems include the development of drug-resistant virus and availability as well as affordability for sufficient 
amounts of the drug in developing countries. Overlapping treatment of the classical strain to the new atypical strain 
can still be expected. 
6. vaccine  isolation, although possible, is not the best way to prevent contagion. vaccination might be a more proper method. 
However, the present vaccine for classical influenza is not applicable to the new mutation of atypical swine flu.  
The development of a new vaccine specific for swine flu is needed and is the present focus of vaccinologists 
worldwide.   As of early June 2009, there were some positive signals from some pharmaceutical companies on 
forthcoming specific vaccines for swine flu. 
7.  Complication The complications of swine flu are similar to those of classical influenza. This is the main problem that leads to some 
cases resulting in death, although not highly prevalent. Pneumonitis and respiratory failure are the most problematic 
and can cause poor outcome in complicated cases.
Abbreviations: PCR, polymerase chain reaction;   WHO, World Health Organization.Biologics: Targets & Therapy 2009:3 380
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disease will be successfully controlled. Finding new drugs 
and vaccine for emerging swine flu is still required to cope 
with this emerging problem worldwide. This review focuses 
on the search for new drugs and a vaccine for swine flu. Data 
from searching all available publications from PubMed, 
Scopus, and ISI databases were included, and non-English 
language papers were excluded.
Concepts on finding new drug  
for swine flu
As previously noted, swine flu is an emerging disease. 
Treatments for swine flu are suggested and the general practice 
guideline for dealing with influenza is applied (Table 3). 
A routine antiviral for influenza is applied. Since amantadine 
and rimantadine are confirmed for drug-resistant strains of 
influenza,88–90 the recommended drugs are oseltamivir and 
zanamivir. In current general practice (Table 4), oseltamivir is 
routinely used in cases with swine flu with good efficacy.88–90 
Focusing on the pharmacological reaction, oseltamivir blocks 
the M2 protein and blocks viral penetration and uncoating.91,92 
According to an US report, no resistance to oseltamivir in 
the emerging swine flu was observed.88–90
However, new drugs for swine flu need to be sought. This 
need is due to several reasons. First, although oseltamivir 
is still effective, drug resistance is expected to develop in 
the near future due to a high volume of use in the pandemic 
scenario. Second, we can expect a genetic instability in the 
swine flu virus. In addition to new drugs, there is also a 
need for the local production of generic drugs of oseltamivir 
in developing countries. This issue needs to be carefully 
considered as drug patent concerns may be an obstacle for 
the local production of oseltamivir in many developing 
countries.
As previously mentioned, this paper will focus in the 
pharmacological dynamic issue of drug development and 
this paper does not discuss the current treatment process 
of swine flu. In order to find new drugs for swine flu, the 
recommended steps are listed below:
1.  The viral sequence of the novel influenza virus must be 
mapped. Luckily, plenty of data are already loaded into 
public databases such as PubMed. At present, a diagnostic 
tool with real-time polymerase chain reaction (PCR) for 
influenza A is available and recommended as a diagnostic 
test by the US Food and Drug Administration (FDA). This 
provided several data on the genomics of the new emerg-
ing virus and helps further clarifies its viral structure. The 
data on sequence and structure of swine flu are useful not 
only for drug development, but also for diagnostic tool 
development.
2.  The next focus should be on proven drugs. The reaction 
between the presently used drug, oseltamivir, and swine 
flu virus has to be clarified. This reaction has to be 
shown at the molecular level. Study by crystallization 
technique is suggested. Simulation by a molecular-
docking technique can be helpful at this point. There are 
some present researches on this stage.93,94 According to 
the homology modeling of the neuraminidase, it can be 
seen that novel mutations are not likely to interfere with 
the active site hence the currently used neuraminidase 
inhibitors (oseltamivir, zanamivir, and peramivir) will 
still be effective against the new virus strain.94 The same 
mechanism of pharmacological reaction, blocking M2, 
can be seen in either classical or novel viruses. However, 
the drugs do not have the same effect in both viruses. 
This might be explained by the difference in required 
energy for drug–virus binding reaction.92 More required 
energy can be seen in case of the novel H1N1 influenza 
virus, which, based on the new viral genomic sequence, 
is larger than that of the classical virus.92
3.  Possible genetic variation at the reaction site should 
also be predicted. This is useful for further calcula-
tion on optimum pharmacological binding energy 
between antiviral drug and virus. The mutated resistant 
portion should be the specific favorable site for our 
pharmacological target. Although a big genetic shift of the 
new virus has not yet been reported, it can be expected. 
Modification of previously used drugs into new drugs 
can be done based on the described data.
4.  The derived drug needs to be tested in vitro and in vivo 
with a special focus on possible adverse effects including 
toxicity, mutagenesis, teratogenesis, and carcinogenesis. 
All drugs must pass and follow WHO recommendations 
with the four complete drug trial stages before becoming 
commercially available. This is needed to confirm that the 
drug is actually effective and pose no unwanted adverse 
effects.
Table 3 Presently available antiviral drugs for influenza treatment
Drugs  Specific site  
of reaction
Route of  
administration
Resistance 
to swine flu
Amantadine  M2 protein Oral Yes
rimantadine  M2 protein Oral Yes
Oseltamivir  Neuraminidase Oral No
Zanamivir  Neuraminidase inhaled No
Peramivir Neuraminidase Oral, intravenous NoBiologics: Targets & Therapy 2009:3 381
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Concepts on finding  
new vaccine for swine flu
Although there are several measures for prevention 
for swine flu including basic sanitation practice (hand-
washing and mask use), isolation, chemoprophylaxis, 
and vaccination, vaccination is expected to be the most 
effective tool. Although there is evidence on the finding 
of immunity to the new virus in some elderly adults,63 this 
might be a cross-protective immunity since there are some 
antigenic similarities to currently or previously circulating 
strains of influenza.94 There is currently no effective vac-
cine for swine flu. The classical influenza vaccine is not 
applicable. Finding a new vaccine for swine flu is the cur-
rent hot topic in medicine.95 The current question is how 
to produce an effective pandemic influenza vaccine.96,97   
Focusing on classical influenza, the problem of the genetic 
shift highlights the problem of the efficacy of the in-use 
influenza vaccine. In the case of the novel influenza swine 
flu, the problem remains. For production of pandemic 
influenza vaccine, the similar process to that of seasonal 
(regular) influenza vaccine can be followed. Nevertheless, 
adding to the basic two major focuses, safety and efficacy, 
for seasonal influenza vaccine, the other two major focuses, 
immunogenicity and timely availability, are also needed 
for pandemic influenza vaccine.94,95 However, the original 
seed virus must be the new virus. This raises the problem 
of production because it is hard to make the new virus 
available in huge amounts. The problem might be solved 
by present biotechnology, but the limitation of technology 
in developing countries also prevents success in local pro-
duction of new vaccine in those settings. There are also 
post-production concerns: “How to test the new vaccine in 
the shortest period?” “How to register the new vaccine in 
each country?” “How to administer the vaccine to the at-risk 
population in each country?”
To find a new vaccine for swine flu, the recommended 
steps are listed below:
1.  It will be necessary to completely map the genome of 
the novel influenza virus. This is the main requirement 
because any new vaccine has to be based on the genomic 
information of the new virus. Luckily, this data is 
presently available. The genomics data of the novel 
influenza virus is freely available on public databases 
such as PubMed.87 According to the recent study by 
Maurer-Stroh and colleagues, the antigenic regions of 
the neuraminidase relevant for vaccine development, 
serological typing, and passive antibody treatment was 
totally different from those of classical influenza.94 This is 
the main reason for asking why the vaccine for classical 
influenza cannot be applied for the novel strain and this 
is also the reason for the need for finding a new vaccine 
specific to the novel virus.
2.  The immunological aspect of the new emerging virus 
must be known by finding the immunogenic part of the 
new virus. The use of immunomics technology might 
help shorten this period. The finding of the epitope is the 
basic primary step to find a new vaccine.
3.  The application of new recombinant biotechnology to 
produce sufficient amount of new original seed virus 
for production of pandemic influenza vaccine must be 
completed.92,93
4.  Post-production testing to assess both safety and efficacy 
of the derived vaccine is required. On one hand, the new 
vaccine has to be well verified before real world use. On 
the other hand, this process has to be as fast as possible 
to cope with the fast emerging pandemic.
5.  Post-marketing surveillance to follow up the effectiveness 
and adverse effect of the new vaccine is needed, similar 
to the routine practice for all new vaccines.
As already noted, a new vaccine has just been manufactured 
and approved by the US FDA.86 However, it should 
be noted that there is still no report on the clinical and 
epidemiological aspect of the new vaccine is only in the 
trial phase. It is not possible to present the data on these 
aspects in this review. This information will be provided 
by future studies.
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